| Medicines/Item |
Section |
Status |
Link Name / Link URL |
| Nintedanib |
08.01 |
Formulary
|
NICE TA347 : Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non-small-cell lung cancer |
| Nintedanib |
08.01 |
Formulary
|
NICE TA379: Nintedanib for treating idiopathic pulmonary fibrosis |
| Abatacept |
10.01.03 |
Restricted Use
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis |
| Abatacept |
10.01.03 |
Restricted Use
|
NICE TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor |
| Abatacept |
10.01.03 |
Restricted Use
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Abciximab |
02.09 |
Restricted Use
|
NICE TA47: Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes |
| Abemaciclib |
08.01.05 |
Formulary
|
NICE TA563: Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer |
| Abemaciclib |
08.01.05 |
Formulary
|
NICE TA579: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy |
| Abiraterone Acetate |
08.03.04.02 |
Formulary
|
NICE TA259 - Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen |
| Abiraterone Acetate |
08.03.04.02 |
Formulary
|
NICE TA387 Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated |
| Aclidinium Bomide |
03.01.02 |
Formulary
|
NICE ESNM8: Chronic obstructive pulmonary disease: aclidinium bromide |
| Adalimumab |
13.05.03 |
Restricted Use
|
NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
| Adalimumab |
13.05.03 |
Restricted Use
|
TA392 Adalimumab for treating moderate to severe hidradenitis suppurativa |
| Adalimumab |
13.05.03 |
Restricted Use
|
NICE TA146: Psoriasis - adalimumab |
| Adalimumab |
10.01.03 |
Restricted Use
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Adalimumab |
10.01.03 |
Restricted Use
|
NICE TA392 Adalimumab for treating moderate to severe hidradenitis suppurativa |
| Adalimumab |
10.01.03 |
Restricted Use
|
NICE TA195: Rheumatoid arthritis - drugs for treatment of arthritis after failure of a TNF inhibitor |
| Adalimumab |
10.01.03 |
Restricted Use
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Adalimumab |
10.01.03 |
Restricted Use
|
NICE TA373: Juvenile idiopathic arthritis- abatacept, adalimumab, etanercept and tocilizumab |
| Adalimumab |
01.05.03 |
Formulary
|
NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease |
| Adalimumab |
01.05.03 |
Formulary
|
NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis |
| Adalimumab |
01.05.03 |
Formulary
|
NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy |
| Adalimumab |
01.05.03 |
Formulary
|
NICE TA187 - Infliximab (review) and adalimumab for the treatment of Crohn’s disease |
| Adefovir Dipivoxil |
05.03.03 |
Restricted Use
|
NICE CG165: Hepatitis B (chronic) - incorporates TA96 |
| Adefovir Dipivoxil |
05.03.03 |
Restricted Use
|
NICE TA96: Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alpha-2a |
| Afatinib |
08.01.05 |
Formulary
|
NICE TA310: Lung cancer (non small cell, EGFR mutation positive) - afatinib |
| Aflibercept |
08.01 |
Formulary
|
NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy |
| Aflibercept |
11.08.02 |
Restricted Use
|
NICE TA294: Macular degeneration (wet age-related) - aflibercept |
| Aflibercept |
11.08.02 |
Restricted Use
|
NICE TA305: Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion |
| Aflibercept |
11.08.02 |
Restricted Use
|
NICE TA409 : Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion |
| Aflibercept |
11.08.02 |
Restricted Use
|
NICE TA346: Aflibercept for treating diabetic macular oedema |
| Aflibercept |
11.08.02 |
Restricted Use
|
NICE TA486: Aflibercept for treating choroidal neovascularisation |
| Alectinib |
08.01.05 |
Formulary
|
NICE TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer |
| Alemtuzumab |
08.02.03 |
Formulary
|
NICE TA312: Alemtuzumab for treating relapsing‑remitting multiple sclerosis |
| Alendronic Acid |
06.06.02 |
Formulary
|
NICE TA464: Bisphosphonates for treating osteoporosis |
| Alendronic Acid Effervescent tablets |
06.06.02 |
Formulary
|
NICE TA464 - Bisphosphonates for treating osteoporosis |
| Alirocumab |
02.12 |
Formulary
|
TA393 Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |
| Alitretinoin |
13.05.01 |
Restricted Use
|
NICE TA177: Eczema (chronic) - alitretinoin |
| Alteplase |
02.10.02 |
Restricted Use
|
NICE TA264 - Alteplase for treating acute ischaemic stroke |
| Alteplase |
02.10.02 |
Non Formulary
|
NICE TA264: Ischaemic stroke (acute) - alteplase |
| Anti-D (Rh0) Immunoglobulin |
14.05.03 |
Non Formulary
|
NICE TA156: Anti-D in pregnant women |
| Apixaban |
02.08.02 |
Formulary
|
NICE TA341: Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism |
| Apixaban |
02.08.02 |
Formulary
|
NICE TA245: Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults |
| Apixaban |
02.08.02 |
Formulary
|
NICE TA275: Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation |
| Apremilast |
10.01.03 |
Restricted Use
|
NICE TA 433: Apremilast for treating active psoriatic arthritis |
| Apremilast |
13.05.02 |
Formulary
|
NICE TA419: Apremilast for treating moderate to severe plaque psoriasis |
| Aripiprazole |
04.02.01 |
Formulary
|
NICE TA292: Bipolar disorder (children) - aripiprazole |
| Aripiprazole |
04.02.01 |
Formulary
|
NICE TA213: Aripiprazole for the treatment of schizophrenia in people aged 15 -17 years |
| Arsenic Trioxide |
08.01.05 |
Formulary
|
NICE TA526: Arsenic trioxide for treating acute promyelocytic leukaemia |
| Asfotase alfa |
09.08.01 |
Restricted Use
|
NICE HST6: Asfotase alfa for treating paediatric-onset hypophosphatasia |
| Atezolizumab |
08.02.03 |
Formulary
|
NICE TA492: Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable |
| Atezolizumab |
08.02.03 |
Formulary
|
NICE TA520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy |
| Atezolizumab |
08.02.03 |
Formulary
|
NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy |
| Atezolizumab |
08.02.03 |
Formulary
|
NICE TA638: Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer |
| Atezolizumab |
08.02.03 |
Formulary
|
NICE TA584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer |
| Atezolizumab |
08.02.03 |
Formulary
|
NICE TA639: Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer |
| Atorvastatin |
02.12 |
Formulary
|
NICE CG181 - Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease |
| Avatrombopag |
09.01.04 |
Formulary
|
NICE TA626: Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure |
| Avelumab |
08.02.03 |
Formulary
|
NICE TA517: Avelumab for treating metastatic Merkel cell carcinoma |
| Avelumab |
08.02.03 |
Formulary
|
NICE TA645: Avelumab with axitinib for untreated advanced renal cell carcinoma |
| Axicabtagene ciloleucel |
08.02.04 |
Formulary
|
NICE TA559: Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies |
| Axitinib |
08.01.05 |
Formulary
|
NICE TA333: Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment |
| Azacitidine |
08.01.03 |
Formulary
|
NICE TA218: Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia |
| Azacitidine |
08.01.03 |
Formulary
|
TA399 Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts |
| Azacitidine |
08.03.01 |
Formulary
|
TA 399 Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts |
| Azathioprine |
10.01.03 |
Formulary
|
CG79 The Management of Rheumatoid Arthritis in Adults |
| Baricitinib |
10.01.03 |
Restricted Use
|
NICE TA466: Baricitinib for moderate to severe rheumatoid arthritis |
| Beclometasone and formoterol |
03.02 |
Formulary
|
NICE ESNM53 Asthma in adults: beclometasone/formoterol dry powder inhaler (Fostair NEXThaler) |
| Belimumab |
10.01.03 |
Restricted Use
|
NICE TA397 Belimumab for treating active autoantibody-positive systemic lupus erythematosus |
| Bendamustine |
08.01.01 |
Formulary
|
NICE TA216: Bendamustine for the first-line treatment of chronic lymphocytic leukaemia |
| Benralizumab |
03.04.02 |
Formulary
|
NICE TA565: Benralizumab for treating severe eosinophilic asthma |
| Bevacizumab |
08.01.05 |
Formulary
|
NICE TA263: Breast cancer with capecitabine |
| Bevacizumab |
08.01.05 |
Formulary
|
NICE TA214: Bevacizmab in combination with taxane |
| Bevacizumab |
08.01.05 |
Formulary
|
NICE TA284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer |
| Bevacizumab |
08.01.05 |
Formulary
|
NICE TA285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab |
| Bevacizumab |
08.01.05 |
Formulary
|
NICE TA212: Colorectal cancer (metastatic) - bevacizumab |
| Bevacizumab |
08.01.05 |
Formulary
|
NICE TA242: Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review) |
| Bivalirudin |
02.08.01 |
Formulary
|
NICE TA230 : Bivalirudin for the treatment of ST-segment-elevation myocardial infarction |
| Blinatumomab |
08.02.03 |
Formulary
|
NICE TA589:Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity |
| Blinatumomab |
08.02.03 |
Formulary
|
NICE TA450: Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia |
| Boceprevir |
05.03.03 |
Restricted Use
|
NICE TA253: Hepatitis C (genotype 1) - boceprevir |
| Bortezomib |
08.01.05 |
Restricted Use
|
NICE TA311: Multiple myeloma - bortezomib (induction therapy |
| Bortezomib |
08.01.05 |
Restricted Use
|
NICE TA299: Leukaemia (chronic myeloid) - bosutinib |
| Bortezomib |
08.01.05 |
Restricted Use
|
NICE TA228: Bortezomib and thalidomide for the first-line treatment of multiple myeloma |
| Bortezomib |
08.01.05 |
Restricted Use
|
NICE TA129: Multiple myeloma - bortezomib |
| Bortezomib |
08.01.05 |
Formulary
|
NICE TA573: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma |
| Bortezomib |
08.01.05 |
Formulary
|
NICE TA311: Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation |
| Bortezomib |
08.01.05 |
Formulary
|
NICE TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma |
| Bortezomib |
08.01.05 |
Formulary
|
NICE TA129: Bortezomib monotherapy for relapsed multiple myeloma |
| Bosutinib |
08.01.05 |
Formulary
|
NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia |
| Botulinum neurotoxin Type A |
04.12 |
Formulary
|
NICE TA605: Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea |
| Botulinum Toxin Type A |
04.07.04.02 |
Formulary
|
NICE TA260: Botulinum toxin type A for the prevention of headaches in adults with chronic migraine |
| Brentuximab vedotin |
08.01.05 |
Formulary
|
NICE TA524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma |
| Brentuximab vedotin |
08.01.05 |
Formulary
|
NICE TA478: Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma |
| Brentuximab vedotin |
08.01.05 |
Formulary
|
NICE TA641: Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma |
| Brentuximab vedotin |
08.01.05 |
Formulary
|
NICE TA577: Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma |
| Brigatinib |
08.01.05 |
Formulary
|
NICE TA571: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib |
| Brodalumab |
10.01.03 |
Restricted Use
|
NICE TA511: Brodalumab for treating moderate to severe plaque psoriasis |
| Cabazitaxel |
08.01.05 |
Formulary
|
NICE TA391 - Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel |
| Cabozantinib |
08.01.05 |
Formulary
|
NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma |
| Cabozantinib |
08.01.05 |
Formulary
|
NICE TA516: Cabozantinib for treating medullary thyroid cancer |
| Cabozantinib |
08.01.05 |
Formulary
|
NICE TA463: Cabozantinib for previously treated advanced renal cell carcinoma |
| Canagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390 - Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
| Canagliflozin |
06.01.02.03 |
Formulary
|
NICE TA315: Canagliflozin in combination therapy for treating type 2 diabetes |
| Cangrelor |
02.09 |
Formulary
|
NICE TA351 : Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti-platelet therapy (terminatedappraisal) |
| Cannabidiol |
04.08.01 |
Formulary
|
NICE TA614: Cannabidiol with clobazam for treating seizures associated with Dravet syndrome |
| Cannabidiol |
04.08.01 |
Formulary
|
NICE TA615: Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome |
| Capecitabine |
08.01.03 |
Formulary
|
NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin |
| Capecitabine |
08.01.03 |
Formulary
|
NICE TA191: Capecitabine for the treatment of advanced gastric cancer |
| Carfilzomib |
08.01.05 |
Formulary
|
NICE TA457: Carfilzomib for previously treated multiple myeloma |
| Carmustine |
08.01.01 |
Formulary
|
NICE TA121:Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma |
| Carmustine |
08.01.01 |
Non Formulary
|
NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide |
| Cemiplimab |
08.01.05 |
Formulary
|
NICE TA592: Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma |
| Ceritinib |
08.01.05 |
Formulary
|
NICE TA395 Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer |
| Ceritinib |
08.01.05 |
Formulary
|
NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer |
| Certolizumab Pegol |
10.01.03 |
Restricted Use
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Certolizumab Pegol |
10.01.03 |
Restricted Use
|
NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs |
| Certolizumab Pegol |
10.01.03 |
Restricted Use
|
NICE TA375: Adalimumab, eternecept, infliximab, certolizumabpegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Certolizumab Pegol |
10.01.03 |
Restricted Use
|
NICE TA415: Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor |
| Certolizumab Pegol |
10.01.03 |
Restricted Use
|
NICE TA574: Certolizumab pegol for treating moderate to severe plaque psoriasis |
| Cetuximab |
08.01.05 |
Restricted Use
|
NICE TA176: Colorectal cancer (first line) - cetuximab |
| Cetuximab |
08.01.05 |
Restricted Use
|
NICE TA172: Head and neck cancer (squamous cell carcinoma) - cetuximab |
| Cetuximab |
08.01.05 |
Restricted Use
|
NICE TA118: Colorectal cancer (metastatic) - bevacizumab & cetuximab |
| Cetuximab |
08.01.05 |
Restricted Use
|
NICE TA145: Head and neck cancer - cetuximab |
| Cetuximab |
08.01.05 |
Restricted Use
|
NICE TA242: TA242 Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review) |
| Cetuximab |
08.01.05 |
Formulary
|
NICE TA473: Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck |
| Cetuximab |
08.01.05 |
Formulary
|
NICE TA439:Cetuximab and panitumumab for previously untreated metastatic colorectal cancer |
| Ciclosporin |
11.08.01 |
Formulary
|
TA369 : Ciclosporin for treating dry eye disease that has not improved despitetreatment with artificial tears |
| Ciclosporin |
10.01.03 |
Formulary
|
CG79 The Management of Rheumatoid Arthritis in Adults |
| Ciclosporin |
01.05.03 |
Formulary
|
NICE NG130: Ulcerative colitis: management |
| Cinacalcet |
09.05.01.02 |
Restricted Use
|
NICE TA117: Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy |
| Cladribine |
08.01.03 |
Formulary
|
NICE TA616: Cladribine for treating relapsing–remitting multiple sclerosis |
| Clopidogrel |
02.09 |
Formulary
|
NICE TA210: Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events |
| Colistimethate inhaler |
05.01.07 |
Restricted Use
|
NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin |
| Collagenase |
10.03.01 |
Non Formulary
|
NICE TA459: Collagenase clostridium histolyticum for treating Dupuytren’s contracture |
| Crizotinib |
08.01.05 |
Formulary
|
NICE TA406 : Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-nonsmall- |
| Crizotinib |
08.01.05 |
Formulary
|
NICE TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer |
| Crizotinib |
08.01.05 |
Formulary
|
NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer |
| Cytarabine-Daunorubicin liposomal |
08.01.03 |
Formulary
|
NICE TA552: Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia |
| Dabigatran |
02.08.02 |
Formulary
|
NICE TA327: Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism |
| Dabigatran |
02.08.02 |
Formulary
|
NICE TA157: Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults |
| Dabigatran |
02.08.02 |
Formulary
|
NICE TA249: Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation |
| Dabrafenib mesilate |
08.01.05 |
Formulary
|
NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma |
| Dabrafenib mesilate |
08.01.05 |
Formulary
|
NICE TA321: Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma |
| Dabrafenib mesilate |
08.01.05 |
Formulary
|
NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma |
| Daclatasvir |
05.03.03.02 |
Restricted Use
|
NICE TA364: Daclatasvir for treating chronic hepatitis C |
| Daclizumab |
08.02.02 |
Formulary
|
NICE TA441: Daclizumab for treating relapsing–remitting multiple sclerosis |
| Dacomitinib |
08.01.05 |
Formulary
|
NICE TA595: Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
TA597: Dapagliflozin with insulin for treating type 1 diabetes |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA418: Dapagliflozin in triple therapy for treating type 2 diabetes |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390 : Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA 288: Dapagliflozin in combination therapy for treating type 2 diabetes |
| Daratumumab |
08.01.05 |
Formulary
|
NICE TA510: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma |
| Daratumumab |
08.01.05 |
Formulary
|
NICE TA573: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma |
| Dasatinib |
08.01.05 |
Formulary
|
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia |
| Dasatinib |
08.01.05 |
Formulary
|
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia |
| Degarelix |
08.03.04.02 |
Formulary
|
NICE TA404: Degarelix for treating advanced hormone-dependent prostate cancer |
| Denosumab |
06.06.02 |
Formulary
|
NICE TA204: Osteoporotic fractures - denosumab |
| Denosumab |
06.06.02 |
Restricted Use
|
TA265 : Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours |
| Dexamethasone intravitreal implant |
11.04.01 |
Restricted Use
|
NICE TA229: Dexamethasone intravitreal implant for the treatment of macular oedema |
| Dexamethasone intravitreal implant |
11.04.01 |
Restricted Use
|
NICE TA349 : Dexamethasone intravitreal implant for treating diabetic macular oedema |
| Dimethyl fumarate |
08.02.04 |
Formulary
|
NICE TA320: Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis |
| Dimethyl fumerate |
13.05.03 |
Formulary
|
NICE TA475: Dimethyl fumarate for treating moderate to severe plaque psoriasis |
| Dinutuximab |
08.02.03 |
Formulary
|
NICE TA538: Dinutuximab beta for treating neuroblastoma |
| Docetaxel |
08.01.05 |
Formulary
|
NICE TA101: Prostate cancer (hormone-refractory) - docetaxel |
| Docetaxel |
08.01.05 |
Formulary
|
NICE TA109: Breast cancer (early) - docetaxel |
| Doxorubicin hydrochloride |
08.01.02 |
Non Formulary
|
NICE TA91: Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan (review) |
| Dronedarone |
02.03.02 |
Formulary
|
NICE TA197: Dronedarone for the treatment of non-permanent atrial fibrillation |
| Dupilumab |
13.05.03 |
Formulary
|
NICE TA534: Dupilumab for treating moderate to severe atopic dermatitis |
| Durvalumab |
08.01.05 |
Formulary
|
NICE TA578: Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation |
| Edoxaban |
02.08.02 |
Formulary
|
NICE TA355: Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation |
| Edoxaban |
02.08.02 |
Formulary
|
NICE TA354: Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism |
| Elbasvir-grazoprevir |
05.03.03.02 |
Restricted Use
|
NICE TA413: Elbasvir–grazoprevir for treating chronic hepatitis C |
| Eltrombopag |
09.01.04 |
Formulary
|
NICE TA293: Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura |
| Eluxadoline |
01.04.02 |
Formulary
|
NICE TA471: Eluxadoline for treating irritable bowel syndrome with diarrhoea |
| Empagliflozin |
06.01.02.03 |
Formulary
|
NICE TA336 : Empagliflozin in combination therapy for treating type 2 diabetes |
| Empagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies fortreating type 2 diabetes |
| Encorafenib |
08.01.05 |
Formulary
|
NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma |
| Entecavir |
05.03.03 |
Restricted Use
|
NICE TA153: Hepatitis B (chronic) - etecavir |
| Entecavir |
05.03.03 |
Restricted Use
|
NICE CG165: Hepatitis B (incorporates TA153) |
| Entrectinib |
08.01.05 |
Formulary
|
NICE TA644: Entrectinib for treating NTRK fusion-positive solid tumours |
| Entrectinib |
08.01.05 |
Formulary
|
NICE TA643: Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer |
| Enzalutamide |
08.03.04.02 |
Formulary
|
NICE TA316: Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen |
| Enzalutamide |
08.03.04.02 |
Formulary
|
NICE TA377: Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated |
| Eplerenone |
02.02.03 |
Formulary
|
NICE NG106: Chronic heart failure in adults: diagnosis and management |
| Eribulin |
08.01.05 |
Formulary
|
NICE TA423- Eribulin for treating advanced or metastatic cancer after 2 or more chemotherapies |
| Erlotinib |
08.01.05 |
Restricted Use
|
NICE TA162: Lung cancer (non-small-cell) 2nd line- erlotinib |
| Erlotinib |
08.01.05 |
Restricted Use
|
NICE TA258: Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line) |
| Erlotinib |
08.01.05 |
Restricted Use
|
NICE TA227: Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy) |
| Erlotinib |
08.01.05 |
Formulary
|
TA374 Erlotinib and Gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy |
| Erlotinib |
08.01.05 |
Formulary
|
TA258 - Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer |
| Erlotinib |
08.01.05 |
Formulary
|
TA227 - Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer |
| Ertugliflozin |
06.01.02.03 |
Formulary
|
NICE TA572: Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes |
| Ertugliflozin |
06.01.02.03 |
Formulary
|
NICE TA583: Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes |
| Etanercept |
10.01.03 |
Restricted Use
|
NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
| Etanercept |
10.01.03 |
Restricted Use
|
NICE TA383: TNF alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Etanercept |
10.01.03 |
Restricted Use
|
NICE TA373: Juvenile idiopathic arthritis- abatacept, adalimumab, etanercept and tocilizumab |
| Etanercept |
10.01.03 |
Restricted Use
|
NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor |
| Etanercept |
10.01.03 |
Restricted Use
|
NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab |
| Etanercept |
10.01.03 |
Restricted Use
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed. |
| Etanercept |
13.05.03 |
Restricted Use
|
NICE TA103: Psoriasis - efalizumab and etanercept |
| Etelcalcetide |
09.05.01.02 |
Restricted Use
|
NICE TA448: Etelcalcetide for treating secondary hyperparathyroidism |
| Everolimus |
08.01.05 |
Formulary
|
NICE T432: Everolimus for advanced renal cell carcinoma after previous treatment |
| Everolimus |
08.01.05 |
Formulary
|
NICE TA421:Everolimus with exemestane for treating advanced breast cancer after endocrine therapy |
| Everolimus |
08.01.05 |
Formulary
|
NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease |
| Everolimus |
08.01.05 |
Non Formulary
|
NICE TA348 : Everolimus for preventing organ rejection in liver transplantation |
| Evolocumab |
02.12 |
Formulary
|
TA394 Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |
| Exemestane |
08.03.04.01 |
Formulary
|
TA112 - Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer |
| Ezetimibe |
02.12 |
Formulary
|
NICE TA385: Ezetimibe for treating primary heterozygous - familial and non-familial hypercholesterolaemia |
| Febuxostat |
10.01.04 |
Formulary
|
TA164 Febuxostat for the management of Hyperuricaemia in People with Gout |
| Finasteride |
06.04.02 |
Formulary
|
NICE CG 97 Lower urinary tract symptoms in men;management |
| Fingolimod |
08.02.04 |
Formulary
|
NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis |
| Fludarabine Phosphate |
08.01.03 |
Formulary
|
NICE TA640: Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant |
| Fludarabine Phosphate |
08.01.03 |
Formulary
|
NICE TA29: Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia |
| Fludarabine Phosphate |
08.01.03 |
Formulary
|
NICE TA119: Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia |
| Fluocinolone intravitreal implant |
11.04.01 |
Formulary
|
NICE TA590 : Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis |
| Fluocinolone intravitreal implant |
11.04.01 |
Formulary
|
NICE TA301: Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy |
| Formoterol/Beclometasone |
03.02 |
Formulary
|
NICE ESNM22 Asthma: beclometasone/formoterol (Fostair) for maintenance and reliever treatment |
| Fremanezumab |
04.07.04.02 |
Formulary
|
NICE TA631: Fremanezumab for preventing migraine |
| Fulvestrant |
08.03.04.01 |
Formulary
|
NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer - not recommended |
| Galantamine M/R capsules |
04.11 |
Formulary
|
Information from NICE |
| Gaviscon®Advance |
01.01.02 |
Formulary
|
NICE CG184: Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management |
| Gefitinib |
08.01.05 |
Formulary
|
NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy |
| Gefitinib |
08.01.05 |
Formulary
|
NICE TA192: Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer |
| Gemcitabine |
08.01.03 |
Formulary
|
NICE TA116: Gemcitabine for the treatment of metastatic breast cancer |
| Gemcitabine |
08.01.03 |
Formulary
|
NICE NG85: Pancreatic cancer in adults: diagnosis and management |
| Gemtuzumab ozogamicin |
08.02.03 |
Formulary
|
NICE TA545: Gemtuzumab ozogamicin for untreated acute myeloid leukaemia |
| Gilteritinib |
08.01.05 |
Formulary
|
NICE TA642: Gilteritinib for treating relapsed or refractory acute myeloid leukaemia |
| Glecaprevir - pibrentasvir |
05.03.03.02 |
Restricted Use
|
NICE TA499: Glecaprevir–pibrentasvir for treating chronic hepatitis C |
| GLIADEL wafer Carmustine 7.6mg |
20 |
Non Formulary
|
NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide |
| Glycopyrronium Bromide |
03.01.02 |
Formulary
|
NICE ESNM9: Chronic obstructive pulmonary disease: Glycopyrronium Bromide |
| Golimumab |
10.01.03 |
Restricted Use
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Golimumab |
10.01.03 |
Restricted Use
|
NICE TA497: Golimumab for treating non-radiographic axial spondyloarthritis |
| Golimumab |
10.01.03 |
Restricted Use
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Golimumab |
10.01.03 |
Restricted Use
|
NICE TA220: Golimumab for the treatment of psoriatic arthritis |
| Golimumab |
10.01.03 |
Restricted Use
|
NICE TA225: Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs |
| Golimumab |
01.05.03 |
Formulary
|
NICE TA329 Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy |
| Guselkumab |
13.05.03 |
Formulary
|
NICE TA521: Guselkumab for treating moderate to severe plaque psoriasis |
| Ibandronic Acid |
06.06.02 |
Formulary
|
NICE TA464: Bisphosphonates for treating osteoporosis |
| Ibandronic Acid |
06.06.02 |
Formulary
|
NICE TA464 - Bisphosphonates for treating osteoporosis |
| Ibrutinib |
08.01.05 |
Formulary
|
NICE TA429: Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation |
| Ibrutinib |
08.01.05 |
Formulary
|
NICE TA491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia |
| Ibrutinib |
08.01.05 |
Formulary
|
NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma |
| Idelalisib |
08.01.05 |
Formulary
|
NICE TA359 -Idelalisib for treating chronic lymphocytic leukaemia |
| Imatinib |
08.01.05 |
Formulary
|
NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours |
| Imatinib |
08.01.05 |
Formulary
|
NICE TA86: Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours |
| Imatinib |
08.01.05 |
Formulary
|
NICE TA70: Guidance on the use of imatinib for chronic myeloid leukaemia |
| Imatinib |
08.01.05 |
Formulary
|
NICE TA209: Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours |
| Imatinib |
08.01.05 |
Formulary
|
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia |
| Imatinib |
08.01.05 |
Formulary
|
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia |
| Infliximab |
01.05.03 |
Formulary
|
NICE TA163: Infliximab for acute exacerbations of ulcerative colitis |
| Infliximab |
01.05.03 |
Formulary
|
NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease |
| Infliximab |
01.05.03 |
Formulary
|
NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis |
| Infliximab |
10.01.03 |
Restricted Use
|
NICE TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor |
| Infliximab |
10.01.03 |
Restricted Use
|
NICE TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis |
| Infliximab |
10.01.03 |
Restricted Use
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Infliximab |
10.01.03 |
Restricted Use
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Infliximab |
13.05.03 |
Non Formulary
|
NICE TA134: Infliximab for psoriasis |
| Infliximab |
13.05.03 |
Restricted Use
|
TA134 - Infliximab for the treatment of adults with psoriasis |
| Infliximab |
01.05.03 |
Formulary
|
NICE TA187 - Infliximab (review) and adalimumab for the treatment of Crohn’s disease |
| Infliximab |
01.05.03 |
Formulary
|
NICE TA163 - Infliximab for acute exacerbations of ulcerative colitis |
| Infliximab |
01.05.03 |
Formulary
|
NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy |
| Inotuzumab ozogamicin |
08.02.03 |
Formulary
|
NICE TA541: Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia |
| Interferon Alfa |
08.02.04 |
Formulary
|
NICE TA75: Interferon alfa (pegylated and nonpegylated) and ribavirin for the treatment of chronic hepatitis C |
| Interferon Beta |
08.02.04 |
Formulary
|
NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis |
| Ipilimumab |
08.01.05 |
Formulary
|
NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma |
| Ipilimumab |
08.01.05 |
Formulary
|
NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma |
| Ipilimumab |
08.01.05 |
Formulary
|
NICE TA581: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma |
| Ipilimumab |
08.01.05 |
Formulary
|
NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma |
| Irinotecan Hydrochloride |
08.01.05 |
Formulary
|
CG131 - Colorectal cancer: The diagnosis and management of colorectal cancer |
| Irinotecan Hydrochloride |
08.01.05 |
Formulary
|
TA307 - Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy |
| Ivabradine |
02.06.03 |
Formulary
|
NICE TA267: Ivabradine for treating chronic heart failure |
| Ivabradine |
02.06.03 |
Formulary
|
NICE CG126: Stable angina: management |
| Ixazomib |
08.01.05 |
Formulary
|
NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma |
| Ixekizumab |
13.05.03 |
Restricted Use
|
NICE TA442: Ixekizumab for treating moderate to severe plaque psoriasis |
| Ixekizumab |
13.05.03 |
Restricted Use
|
NICE TA537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs |
| Ixekizumab |
10.01.03 |
Formulary
|
NICE TA537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs |
| Lanadelumab |
03.04.03 |
Formulary
|
NICE TA606: Lanadelumab for preventing recurrent attacks of hereditary angioedema |
| Lapatinib |
08.01.05 |
Non Formulary
|
NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer |
| Larotrectinib |
08.02.04 |
Formulary
|
NICE TA630: Larotrectinib for treating NTRK fusion-positive solid tumours |
| Ledipasvir - Sofosbuvir |
05.03.03.02 |
Restricted Use
|
NICE TA363 - Ledipasvir-sofosbuvir for treating Chronic Hepatitis C |
| Leflunomide |
10.01.03 |
Formulary
|
CG79 The Management of Rheumatoid Arthritis in Adults |
| Lenalidomide |
08.02.04 |
Formulary
|
NICE TA171: Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy |
| Lenalidomide |
08.02.04 |
Formulary
|
NICE TA322: Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality |
| Lenalidomide |
08.02.04 |
Formulary
|
NICE TA627: Lenalidomide with rituximab for previously treated follicular lymphoma |
| Lenalidomide |
08.02.04 |
Formulary
|
NICE TA586: Lenalidomide plus Dexamethasone for multiple myeloma after 1 treatment with bortezomib |
| Lenalidomide |
08.02.04 |
Formulary
|
NICE TA587: Lenalidomide plus Dexamethasone for previously untreated multiple myeloma |
| Lenalidomide plus Dexamethasone |
08.02.04 |
Formulary
|
NICE TA 586: Lenalidomide plus Dexamethasone for multiple myeloma after 1 treatment with bortezomib |
| Lenalidomide plus Dexamethasone |
08.02.04 |
Formulary
|
NICE TA 587: Lenalidomide plus Dexamethasone for previously untreated multiple myeloma |
| Lenvatinib |
08.01.05 |
Formulary
|
NICE TA498 - Lenvatinib with everolimus for previously treated advanced renal cell carcinoma |
| Lenvatinib |
08.01.05 |
Formulary
|
NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine |
| Lenvatinib |
08.01.05 |
Formulary
|
NICE TA551: Lenvatinib for untreated advanced hepatocellular carcinoma |
| Letermovir |
05.03.02.02 |
Formulary
|
NICE TA591: Letermovir for preventing cytomegalovirus disease after a stem cell transplant |
| Liraglutide |
06.01.02.03 |
Formulary
|
NICE NG28: Type 2 diabetes in adults:management |
| Lorlatinib |
08.01.05 |
Formulary
|
NICE TA628: Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer |
| Lubiprostone |
01.06.07 |
Non Formulary
|
NICE TA318 :Lubiprostone for treating chronic idiopathic constipation |
| Lumacaftor-ivacaftor |
08.01.02 |
Non Formulary
|
TA398 Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation |
| Lusutrombopag |
09.01.04 |
Formulary
|
NICE TA617: Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure |
| Mannitol Dry Powder |
03.07 |
Formulary
|
TA266 - Mannitol dry powder for inhalation for treating cystic fibrosis |
| Mannitol inhalation |
20 |
Non Formulary
|
NICE TA266 Cystic fibrosis - mannitol dry powder for inhalation (TA266) |
| Mepolizumab |
03.04.02 |
Restricted Use
|
NICE TA431: Mepolizumab for treating severe refractory eosinophilic asthma |
| Methotrexate |
10.01.03 |
Formulary
|
CG79 The Management of Rheumatoid Arthritis in Adults |
| Methylprednisolone |
06.03.02 |
Non Formulary
|
NICE CG8: Multiple Sclerosis; management in primary and secondary care. |
| Midostaurin |
08.01.05 |
Formulary
|
NICE TA523: Midostaurin for untreated acute myeloid |
| Mifamurtide |
08.02.04 |
Formulary
|
NICE TA235: Osteosarcoma - mifamurtide |
| Mirabegron |
07.04.02 |
Formulary
|
NICE TA290: Mirabegron for overactive bladder |
| Naftidrofuryl Oxalate |
02.06.04 |
Formulary
|
NICE TA223: Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease |
| Naldemedine |
01.06.06 |
Formulary
|
NICE TA651: Naldemedine for treating opioid-induced constipation |
| Nalmefene |
04.10.01 |
Formulary
|
NICE TA325: Nalmefene for reducing alcohol consumption in people with alcohol dependence |
| Naloxegol |
01.06.06 |
Formulary
|
NICE TA345: Naloxegol for treating opioid-induced constipation |
| Naltrexone |
04.10.03 |
Restricted Use
|
NICE TA115: Drug misuse - naltrexone |
| Naltrexone-bupropion |
04.05.02 |
Non Formulary
|
NICE TA494: Naltrexone–bupropion for managing overweight and obesity |
| Natalizumab |
08.02.04 |
Formulary
|
NICE TA127: Multiple sclerosis - natalizumab |
| Neratinib |
08.03.04.01 |
Formulary
|
NICE TA612: Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab |
| Nilotinib |
08.01.05 |
Formulary
|
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia |
| Nilotinib |
08.01.05 |
Formulary
|
NICE TA 426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia |
| Nilotinib |
08.01.05 |
Formulary
|
NICE TA251: Leukaemia (chronic myeloid, first line) - dasatinib, nilotinib and standard-dose imatinib |
| Nilotinib |
08.01.05 |
Formulary
|
NICE TA241: Dasatinib, nilotinib and high dose imatinib for CML |
| Niraparib |
08.01.05 |
Formulary
|
NICE TA528: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer |
| Nivolumab |
08.02.04 |
Restricted Use
|
TA400 Nivolumab in combination with ipilimumab for treating advanced melanoma |
| Nivolumab |
08.02.04 |
Restricted Use
|
TA384 Nivolumab for treating advanced (unresectable or metastatic) melanoma |
| Nivolumab |
08.02.03 |
Formulary
|
NICE TA 462: Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma |
| Nivolumab |
08.02.03 |
Formulary
|
NICE TA417: Nivolumab for previously treated advanced renal cell carcinoma |
| Nivolumab |
08.02.03 |
Formulary
|
NICE TA581:Nivolumab with ipilimumab for untreated advanced renal cell carcinoma |
| Nivolumab |
08.02.03 |
Formulary
|
NICE TA490: Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy |
| Nivolumab |
08.02.03 |
Formulary
|
NICE TA558: Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease |
| Nivolumab |
08.02.03 |
Formulary
|
NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma |
| Nivolumab |
08.02.03 |
Formulary
|
NICE TA484: Nivolumab for previously treated non-squamous non-small-cell lung cancer |
| Nivolumab |
08.02.03 |
Formulary
|
NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma |
| Nivolumab |
08.02.03 |
Formulary
|
NICE TA483: Nivolumab for previously treated squamous non-small-cell lung cancer |
| Nivolumab |
08.02.03 |
Formulary
|
NICE TA655: Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy |
| Nusinersen® |
10.02 |
Formulary
|
NICE TA588: Nusinersen for treating spinal muscular atrophy |
| Obeticholic acid |
01.09.01 |
Restricted Use
|
NICE TA443: Obeticholic acid for treating primary biliary cholangitis |
| Obinutuzumab |
08.02.03 |
Formulary
|
NICE TA472: Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab |
| Obinutuzumab |
08.02.03 |
Formulary
|
NICE TA343: Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia |
| Obinutuzumab |
08.02.03 |
Formulary
|
NICE TA513: Obinutuzumab for untreated advanced follicular lymphoma |
| Obinutuzumab |
08.02.03 |
Formulary
|
NICE TA629: Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab |
| Ocrelizumab |
08.02.03 |
Formulary
|
NICE TA533: Ocrelizumab for treating relapsing–remitting multiple sclerosis |
| Ocrelizumab |
08.02.03 |
Formulary
|
NICE TA585: Ocrelizumab for treating primary progressive multiple sclerosis |
| Ocriplasmin |
11.08.02 |
Restricted Use
|
NICE TA297: Ocriplasmin for treating vitreomacular traction |
| Ofatumumab |
08.02.03 |
Formulary
|
NICE TA202: Ofatumumab for the treatment of chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab |
| Ofatumumab |
08.02.03 |
Formulary
|
NICE TA344 : Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia |
| Olaparib |
08.01.05 |
Formulary
|
NICE TA620: Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer |
| Olaparib |
08.01.05 |
Formulary
|
NICE TA598: Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy |
| Olaratumab |
08.01.05 |
Formulary
|
NICE TA465: Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma |
| Omalizumab |
03.04.02 |
Restricted Use
|
NICE TA339: Omalizumab for previously treated chronic spontaneous urticaria |
| Omalizumab |
03.04.02 |
Restricted Use
|
NICE TA278 - Omalizumab for treating severe persistent allergic asthma (review of technology appraisal guidance 133 and 201) |
| Omalizumab |
03.04.02 |
Non Formulary
|
NICE TA278: Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201) |
| Ombitasvir with Paritaprevir and Ritonavir |
05.03.03.02 |
Formulary
|
NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C |
| Osimertinib |
08.01.05 |
Formulary
|
NICE TA654: Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer |
| Osimertinib |
08.01.05 |
Formulary
|
NICE TA416 Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer |
| Osimertinib |
08.01.05 |
Formulary
|
NICE TA653: Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer |
| Oxaliplatin |
08.01.05 |
Restricted Use
|
NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin |
| Paclitaxel |
08.01.05 |
Formulary
|
NICE TA284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer |
| Paclitaxel |
08.01.05 |
Formulary
|
NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Paclitaxel |
08.01.05 |
Formulary
|
NICE TA55: Guidance on the use of paclitaxel in the treatment of ovarian cancer |
| Paclitaxel |
08.01.05 |
Formulary
|
NICE TA108: Paclitaxel for the adjuvant treatment of early node-positive breast cancer |
| Paclitaxel - Albumin Bound Formulation |
08.01.05 |
Formulary
|
NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer |
| Palbociclib |
08.01.05 |
Formulary
|
NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer |
| Palbociclib |
08.01.05 |
Formulary
|
NICE TA619: Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer |
| Panitumumab |
08.01.05 |
Formulary
|
NICE TA439:Cetuximab and panitumumab for previously untreated metastatic colorectal cancer |
| Panitumumab |
08.01.05 |
Non Formulary
|
NICE TA242: Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review) |
| Panobinostat |
08.01.05 |
Formulary
|
NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments |
| Parenteral Nutrition |
09.03 |
Non Formulary
|
CG32: Oral nutrition support, enteral tube feeding and Parenteral Nutrition |
| Patiromer calcium |
09.02.01.01 |
Formulary
|
NICE TA623: Patiromer for treating hyperkalaemia |
| Pazopanib |
08.01.05 |
Formulary
|
NICE TA215: Renal cell carcinoma (first line metastatic) - pazopanib |
| Pegaptanib Sodium |
11.08.02 |
Non Formulary
|
NICE TA155: guidance on pegaptanib in AMD (August 2008) |
| PEGASPARGASE |
20 |
Non Formulary
|
NICE TA408: Pegaspargase for treating acute lymphoblastic leukaemia |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA300: Hepatitis C (children and young people) - peginterferon alfa and ribavirin |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA106: Hepatitis C - peginterferon alfa & ribavirin |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA75: Hepatitis C - pegylated interferons, ribavirin & alfa interferon |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA200: Hepatitis C - peginterferon alfa & ribavirin |
| Peginterferon Alfa |
08.02.04 |
Restricted Use
|
NICE TA200: Hepatitis C - peginterferon alfa and ribavirin |
| Peginterferon Alfa |
08.02.04 |
Restricted Use
|
NICE TA300: Hepatitis C (children and young people) - peginterferon alfa and ribavirin |
| Peginterferon Alfa |
08.02.04 |
Restricted Use
|
NICE TA106: Hepatitis C - peginterferon alfa and ribavirin |
| Peginterferon Alfa |
08.02.04 |
Restricted Use
|
NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon |
| Peginterferon Beta-1a |
08.02.04 |
Formulary
|
NICE TA624: Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis |
| Pegloticase |
20 |
Non Formulary
|
NICE TA291: Pegloticase not recommended for severe chronic gout |
| Pembrolizumab |
08.02.03 |
Formulary
|
NICE TA557: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer |
| Pembrolizumab |
08.02.03 |
Formulary
|
NICE TA519: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy |
| Pembrolizumab |
08.02.03 |
Formulary
|
NICE TA553: Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence |
| Pembrolizumab |
08.02.03 |
Formulary
|
NICE TA540: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma |
| Pembrolizumab |
08.02.03 |
Formulary
|
NICE TA522: Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable |
| Pembrolizumab |
08.02.03 |
Formulary
|
NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer |
| Pembrolizumab |
08.02.03 |
Formulary
|
NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy |
| Pembrolizumab |
08.02.03 |
Formulary
|
NICE TA357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab |
| Pembrolizumab |
08.02.03 |
Formulary
|
NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab |
| Pembrolizumab |
08.02.03 |
Formulary
|
NICE TA600: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer |
| Pemetrexed |
08.01.03 |
Formulary
|
TA402: Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin |
| Pemetrexed |
08.01.03 |
Formulary
|
NICE TA190:Pemetrexed for the maintenance treatment of non-small-cell lung cancer |
| Pemetrexed |
08.01.03 |
Formulary
|
NICE TA124: Pemetrexed for the treatment of non-small-cell lung cancer |
| Pentosan polysulfate sodium |
07.04.03 |
Formulary
|
NICE TA610: Pentosan polysulfate sodium for treating bladder pain syndrome |
| Peptac®Liquid |
01.01.02 |
Formulary
|
NICE CG184: Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management |
| Perampanel |
04.08.01 |
Formulary
|
NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care |
| Pertuzumab |
08.01.05 |
Formulary
|
NICE TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer |
| Pertuzumab |
08.01.05 |
Formulary
|
NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer |
| Pertuzumab |
08.01.05 |
Formulary
|
NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer |
| Pharmalgen |
03.04.02 |
Restricted Use
|
TA246 - Pharmalgen for the treatment of bee and wasp venom allergy |
| Pimecrolimus |
13.05.03 |
Formulary
|
NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema) |
| Pirfenidone |
03.11 |
Restricted Use
|
NICE TA504: Pirfenidone for treating idiopathic pulmonary fibrosis |
| pirfenidone |
20 |
Non Formulary
|
NICE TA282: Idiopathic pulmonary fibrosis - pirfenidone |
| Pixantrone |
08.01.02 |
Formulary
|
NICE TA306: Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin’s B‑cell lymphoma |
| Polatuzumab vedotin |
08.02.03 |
Formulary
|
NICE TA649: Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma |
| Pomalidomide |
08.02.04 |
Formulary
|
NICE TA 427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib |
| Ponatinib |
08.01.05 |
Formulary
|
NICE TA451: Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia |
| Prasugrel |
02.09 |
Formulary
|
NICE TA317: Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes |
| Prucalopride |
01.06.07 |
Formulary
|
NICE TA211: Prucalopride for the treatment of chronic constipation in women |
| Raloxifene Hydrochloride |
06.04.01.01 |
Non Formulary
|
NICE TA160: quick reference guide on osteoporosis |
| Ranibizumab |
11.08.02 |
Restricted Use
|
NICE TA155 - Ranibizumab and pegaptanib for the treatment of age-related macular degeneration |
| Ranibizumab |
11.08.02 |
Restricted Use
|
NICE TA298: Choroidal neovascularisation (pathological myopia) - ranibizumab |
| Ranibizumab |
11.08.02 |
Restricted Use
|
NICE TA283: Macular oedema (retinal vein occlusion) - ranibizumab: guidance |
| Ranibizumab |
11.08.02 |
Restricted Use
|
NICE TA274: Macular oedema (diabetic) - ranibizumab |
| Ranolazine |
02.06.03 |
Formulary
|
NICE CG126: Stable angina: management |
| Regorafenib |
08.01.05 |
Formulary
|
NICE TA488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours |
| Regorafenib |
08.01.05 |
Formulary
|
NICE TA555: Regorafenib for previously treated advanced hepatocellular carcinoma |
| Reslizumab |
03.04.02 |
Restricted Use
|
NICE TA479: Reslizumab for treating severe eosinophilic asthma |
| Retigabine |
04.08.01 |
Formulary
|
NICE TA232: Retigabine for the adjunctive treatment of adults with partial onset seizures in epilepsy with and without secondary generalisation |
| Ribavirin |
05.03.05 |
Restricted Use
|
NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon |
| Ribavirin |
05.03.05 |
Restricted Use
|
NICE TA106: Hepatitis C - peginterferon alfa and ribavirin |
| Ribavirin |
05.03.05 |
Restricted Use
|
NICE TA300: Hepatitis C (children and young people) - peginterferon alfa and ribavirin |
| Ribavirin |
05.03.05 |
Restricted Use
|
NICE TA200: Hepatitis C - peginterferon alfa and ribavirin |
| Ribociclib |
08.01.05 |
Formulary
|
NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer |
| Ribociclib |
08.01.05 |
Formulary
|
NICE TA593: Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer |
| Rifaximin |
05.01.07 |
Formulary
|
NICE TA337 : Rifaximin for preventing episodes of overt hepatic encephalopathy |
| Riluzole |
04.09.03 |
Formulary
|
NICE TA 20: Guidance on the use of Riluzole (Rilutek) for the treatment of Motor Neurone Disease |
| Risankizumab |
13.05.03 |
Formulary
|
NICE TA596: Risankizumab for treating moderate to severe plaque psoriasis |
| Risedronate |
06.06.02 |
Formulary
|
NICE TA464: Bisphosphonates for treating osteoporosis |
| Rituximab (rheumatology) |
10.01.03 |
Restricted Use
|
NICE TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor |
| Rituximab (rheumatology) |
10.01.03 |
Restricted Use
|
NICE TA308: Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis |
| Rituximab iv |
08.02.03 |
Formulary
|
NICE TA137: Lymphoma (follicular non-Hodgkin's) - rituximab |
| Rituximab iv |
08.02.03 |
Formulary
|
NICE TA226: Lymphoma (follicular non-Hodgkin’s) - rituximab |
| Rituximab iv |
08.02.03 |
Formulary
|
NICE TA243: Rituximab for the first-line treatment of stage III-IV follicular lymphoma |
| Rituximab iv |
08.02.03 |
Formulary
|
NICE TA174: Leukaemia (chronic lymphocytic, first line) - rituximab |
| Rituximab iv |
08.02.03 |
Formulary
|
NICE TA65: Non-Hodgkin’s lymphoma - rituximab |
| Rituximab iv |
08.02.03 |
Formulary
|
NICE TA193: Leukaemia (chronic lymphocytic, relapsed) - rituximab |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA261: Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA287: Rivaroxaban for treating PE and preventing recurrent venous thromboembolism |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA335 : Rivaroxaban for preventing adverse outcomes after Acute management of Acute coronary syndrome |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA607: Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease |
| Roflumilast |
03.03.03 |
Restricted Use
|
NICE TA461: Roflumilast for treating chronic obstructive pulmonary disease |
| Romiplostim |
09.01.04 |
Formulary
|
NICE TA221: Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura |
| Rucaparib |
08.02.04 |
Formulary
|
NICE TA611: Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer |
| Ruxolitinib |
08.01.05 |
Formulary
|
NICE TA386 Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis |
| Sacubitril valsartan |
02.05.05 |
Formulary
|
NICE TA388 - Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction |
| Sarilumab |
08.02.04 |
Restricted Use
|
NICE TA485: Sarilumab for moderate to severe rheumatoid arthritis |
| Sarilumab |
10.01.03 |
Restricted Use
|
NICE TA485: Sarilumab for moderate to severe rheumatoid arthritis |
| Secukinumab |
13.05.03 |
Restricted Use
|
NICE TA350: Secukinumab for treating moderate to severe plaque psoriasis |
| Secukinumab |
13.05.03 |
Restricted Use
|
NICE TA407: Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors |
| Secukinumab |
10.01.03 |
Restricted Use
|
NICE TA350 : Secukinumab for treating moderate to severe plaque psoriasis |
| Semaglutide |
06.01.02.03 |
Formulary
|
NICE NG28: Type 2 diabetes in adults:management |
| Simeprevir |
05.03.03.02 |
Restricted Use
|
NICE TA361 - Simprevir in combination with sofosbuvir for treating genotype 1 or 4 Chronic Hepatitis C |
| Simeprevir |
05.03.03.02 |
Restricted Use
|
NICE TA331: Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C |
| Sodium zirconium cyclosilicate |
09.02.01.01 |
Formulary
|
NICE TA599: Sodium zirconium cyclosilicate for treating hyperkalaemia |
| Sofosbuvir-velpatasvir-voxilaprevir |
05.03.03.02 |
Restricted Use
|
NICE TA507: Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C |
| Sofosubvir-velpatasvir |
05.03.03.02 |
Restricted Use
|
NICE TA430: Sofosbuvir–velpatasvir for treating chronic hepatitis C |
| Somatropin |
06.05.01 |
Formulary
|
NICE TA64: Growth hormone deficiency (adults) - human growth hormone |
| Somatropin |
06.05.01 |
Formulary
|
NICE TA188: Human growth hormone (somatropin) for the treatment of growth failure in children (review) |
| Sorafenib |
08.01.05 |
Formulary
|
NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine |
| Sorafenib |
08.01.05 |
Formulary
|
NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma |
| Sotagliflozin |
06.01.02.03 |
Formulary
|
NICE TA622: Sotagliflozin with insulin for treating type 1 diabetes |
| Sulfasalazine enteric coated |
10.01.03 |
Formulary
|
CG79 The Management of Rheumatoid Arthritis in Adults |
| Sunitinib |
08.01.05 |
Formulary
|
NICE TA179: Gastrointestinal stromal tumours - sunitinib |
| Sunitinib |
08.01.05 |
Formulary
|
NICE TA178: Renal cell carcinoma |
| Sunitinib |
08.01.05 |
Formulary
|
NICE TA169: Renal cell carcinoma - sunitinib |
| Sunitinib |
08.01.05 |
Formulary
|
NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease |
| Tacrolimus |
08.02.02 |
Formulary
|
NICE TA482:Immunosuppressive therapy for kidney transplants in children and young people |
| Tacrolimus |
08.02.02 |
Formulary
|
NICE TA481:Immunosuppressive therapy for kidney transplant in adults |
| Tacrolimus Ointment 0.03% and 0.10% |
13.05.03 |
Formulary
|
NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema) |
| Talimogene laherparepvec |
08.01.05 |
Formulary
|
NICE TA410: Talimogene laherparepvec for treating unresectable metastatic melanoma |
| Tegafur with Uracil |
08.01.03 |
Formulary
|
NICE TA61: Capcitabine and tegafur - Colorectal cancer |
| Telaprevir |
05.03.03 |
Restricted Use
|
NICE TA252: Hepatitis C (genotype 1) - telaprevir |
| Telbivudine |
05.03.03.01 |
Restricted Use
|
NICE TA154: Hepatitis B - telbivudine |
| Temozolomide |
08.01.05 |
Formulary
|
NICE TA23: Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer) |
| Temozolomide |
08.01.05 |
Formulary
|
NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide |
| Temsirolimus |
08.01.05 |
Formulary
|
NICE TA207: Mantle cell lymphoma (relapsed) - temsirolimus (terminated appraisal) |
| Temsirolimus |
08.01.05 |
Formulary
|
NICE TA178: temsirolimus for first-line treatment of advanced and/or metastatic renal cell carcinoma |
| Tenofovir Disproxil |
05.03.01 |
Restricted Use
|
NICE TA173: Hepatitis B (chronic) - tenofovir disoproxil |
| Tenofovir Disproxil |
05.03.01 |
Restricted Use
|
NICE CG165: Hepatitis B (chronic) - incorporates TA173 |
| Teriflunomide |
08.02.04 |
Formulary
|
NICE TA303: Teriflunomide for treating relapsing–remitting multiple sclerosis |
| Teriparatide |
06.06.01 |
Formulary
|
NICE TA161: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women |
| Thalidomide |
08.02.04 |
Formulary
|
NICE TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma |
| Ticagrelor |
02.09 |
Formulary
|
NICE TA236: Ticagrelor for the treatment of acute coronary syndromes |
| Ticagrelor |
02.09 |
Formulary
|
NICE TA420:Ticagrelor for preventing atherothrombotic ardial infarction |
| Tildrakizumab |
13.05.03 |
Formulary
|
NICE TA575: Tildrakizumab for treating moderate to severe plaque psoriasis |
| Tisagenlecleucel |
08.01.05 |
Formulary
|
NICE TA554: Tisagenlecleucel for treating relapsed orrefractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years |
| Tisagenlecleucel |
08.01.05 |
Formulary
|
NICE TA567: Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies |
| Tivozanib |
08.01.05 |
Formulary
|
NICE TA512: Tivozanib for treating advanced renal cell carcinoma |
| Tobramycin inhaler |
05.01.04 |
Restricted Use
|
NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin |
| Tocilizumab |
10.01.03 |
Restricted Use
|
NICE TA247: Tocilizumab for the treatment of rheumatoid arthritis |
| Tocilizumab |
10.01.03 |
Restricted Use
|
NICE TA238: Tocilizumab for the treatment of systemic juvenile idiopathic arthritis |
| Tocilizumab |
10.01.03 |
Restricted Use
|
NICE TA518: Tocilizumab for treating giant cell arteritis |
| Tocilizumab |
10.01.03 |
Restricted Use
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Tofacitinib |
01.05.03 |
Formulary
|
NICE TA547: Tofacitinib for moderately to severely active ulcerative colitis |
| Tofacitinib |
10.01.03 |
Formulary
|
NICE TA480: Tofacitinib for moderate to severe rheumatoid arthritis |
| Tofacitinib |
10.01.03 |
Formulary
|
NICE TA543: Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs |
| Tolvaptan |
06.05.02 |
Restricted Use
|
NICE TA358: Tolvaptan for treating autosomal dominant polycystic kidney disease |
| Topotecan |
08.01.05 |
Formulary
|
TA389 Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Topotecan |
08.01.05 |
Formulary
|
NICE TA184: Lung cancer (small-cell) - topotecan |
| Topotecan |
08.01.05 |
Formulary
|
NICE TA183: Cervical cancer (recurrent) - topotecan |
| Trabectedin |
08.01.05 |
Formulary
|
NICE TA185: Soft tissue sarcoma - trabectedin |
| Trametinib |
08.01.05 |
Formulary
|
NICE TA396 Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma |
| Trametinib |
08.01.05 |
Formulary
|
NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma |
| Trastuzumab |
08.01.05 |
Formulary
|
NICE NG101 Early and locally advanced breast cancer diagnosis and managment |
| Trastuzumab |
08.01.05 |
Formulary
|
NICE TA34: Guidance on the use of trastuzumab for the treatment of advanced breast cancer |
| Trastuzumab |
08.01.05 |
Formulary
|
NICE TA208: Trastuzumab for the treatment of HER2-positive metastatic gastric cancer |
| Trastuzumab |
08.01.05 |
Formulary
|
NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer |
| Trastuzumab emtansine |
08.01.05 |
Formulary
|
NICE TA632: Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer |
| Trastuzumab emtansine |
08.01.05 |
Formulary
|
NICE TA458: Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane |
| Treosulfan |
08.01.01 |
Formulary
|
NICE TA640: Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant |
| Trifluridine tipiracil |
08.01.03 |
Formulary
|
NICE TA405: Trifluridine–tipiracil for previously treated metastatic colorectal cancer |
| Umeclidinium Bromide |
03.01.02 |
Formulary
|
NICE ESNM52: Chronic obstructive pulmonary disease: umeclidinium inhaler (Incruse) |
| Ustekinumab |
01.05.03 |
Formulary
|
NICE TA456 Ustekinumab for moderately to severely active Crohn’s disease after previous treatment |
| Ustekinumab |
01.05.03 |
Formulary
|
NICE TA633: Ustekinumab for treating moderately to severely active ulcerative colitis |
| Ustekinumab |
13.05.03 |
Formulary
|
TA180 - Ustekinumab for the treatment of adults with moderate to severe psoriasis |
| Ustekinumab |
13.05.03 |
Formulary
|
NICE TA340: Ustekinumab for treating active psoriatic arthritis |
| Ustekinumab |
13.05.03 |
Formulary
|
NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
| Ustekinumab |
13.05.03 |
Formulary
|
NICE TA456: Ustekinumab for moderately to severely active Crohn’s disease after previous treatment |
| Varenicline |
04.10.02 |
Formulary
|
NICE TA123: Varenicline |
| Vedolizumab |
01.05.03 |
Formulary
|
NICE TA352: Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy |
| Vedolizumab |
01.05.03 |
Formulary
|
NICE TA342: Vedolizumab for treating moderately to severely active ulcerative colitis |
| Vemurafenib |
08.01.05 |
Formulary
|
NICE TA414: Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma |
| Vemurafenib |
08.01.05 |
Formulary
|
NICE TA269: Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib |
| Venetoclax |
08.01.05 |
Formulary
|
NICE TA487: Venetoclax for treating chronic lymphocytic leukaemia |
| Venetoclax |
08.01.05 |
Formulary
|
NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia |
| Vilanterol/Fluticasone furoate |
03.02 |
Formulary
|
NICE ESM34 Asthma: fluticasone furoate/vilanterol (Relvar Ellipta) combination inhaler |
| Vinflunine |
08.01.04 |
Non Formulary
|
NICE TA272: Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine |
| Vinorelbine |
08.01.04 |
Formulary
|
NICE CG81 : Advanced breast cancer: Diagnosis and treatment |
| Vismodegib |
08.01.05 |
Formulary
|
NICE TA489: Vismodegib for treating basal cell carcinoma |
| Vortioxetine |
04.03.03 |
Formulary
|
TA367 - Vortioxetine for treating major depressive episodes |
| Zopiclone |
04.01.01 |
Formulary
|
NICE TA77: Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia |
